Want to join the conversation?
$AMGN and $ARWR announced two agreements to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease. Under one agreement, $AMGN receives a worldwide, exclusive license to $ARWR's RNAi ARC-LPA program. These RNAi molecules are designed to reduce elevated lipoprotein, which is a risk factor for cardiovascular disease.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.